thought call strength
weather storm clinic catalyst
focu balanc
weve consist character stalwart among larg cap biotech
name view reinforc disrupt caus pandem
notabl highli encourag guidanc maintain suggest may
impact busi line whole amgen abl weather storm
acknowledg busi line could temporarili impact name prolia given
need in-offic inject may off-set otezla given oral rout
administr even enbrel could benefit patient less like switch therapi
pandem also see strength grow biosimilar franchis current track
sale note risk associ result enbrel ip appeal
think anyth case would kick back district court delay
potenti launch biosimilar look ahead key clinic catalyst remain track
data updat albeit nsclc expect virtual meet late may/
earli june phase tezepelumab data sever uncontrol asthma remain track late
omecamtiv mecarbil importantli also expect
monotherapi data phase pivot trial nsclc later year overal
continu like set despit overarch uncertainti support
outperform rate tp
biosimilar franchis core long-term thesi strong perform
may earli determin impact pandem near-term name
demand think adopt lower cost biosimilar reliabl suppli may
acceler mani health system current strain due covid note
end captur trastuzumab segment bevacizumab
segment us expect trajectori continu expand decemb
pdufa biosimilar rituxan
model updates/risk ep updat due chang
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater current
forecast assum greater expect growth biosimilar
franchis slower expect declin base busi
also assum posit data readout pipelin asset
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis also assum neg data
readout pipelin asset
 close
impact pipelin updat although rel non-specif state
clinic trial enrol paus trial key upcom trial
rel unaffect look toward potenti treatment
develop antibodi also run
trial otezla late-stag covid patient help mitig respiratori distress
present data virtual scientif program may
updat result phase studi advanc solid tumor still
expect data potenti pivot monotherapi phase trial nsclc later
includ least month data
updat includ phase data psma bcma
also present updat result phase
target patient r/r aml look biosimilar look potenti regulatori
approv abp rituxan biosimilar pdufa date otezla updat includ
phase data mild-to-moder psoriasi patient move asthma compani
expect phase navig data tezepelumab final data omecamtiv
mecarbil phase galactic-hf remain track broadli speak amgen
announc plan end neurosci research earli develop program base
challeng develop drug neurolog space
model adjust model adjust weve made adjust throughout market
portfolio reflect on-going commerci trend weve also increas biosimilar revenu due
continu out-performance busi reduc xgeva final also
reduc prolia estim anticip disrupt recoveri gradual
begin tax expens adjust reflect current margin figur
model chang
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
